Siwek Marcin, Gorostowicz Aleksandra
Department of Affective Disorders, Department of Psychiatry, Cracow, Poland.
Department of Psychiatry, Jagiellonian University Medical College, Cracow, Poland.
Clin Psychopharmacol Neurosci. 2021 Aug 31;19(3):568-571. doi: 10.9758/cpn.2021.19.3.568.
Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. It seems to have a favorable metabolic profile and low risk of causing adverse interactions. Here we present a case of a 25-year old female patient with treatment-resistant ultra-rapid cycling bipolar disorder, obesity, hypothyroidism, and epilepsy. Because of predominant depressive symptoms, occasional occurrence of brief psychotic symptoms and patient's somatic comorbidities, treatment with lurasidone was initiated. Clinical improvement was observed 3 weeks and cessation of ultra-rapid cycling course of the disease 8 weeks after the beginning of lurasidone treatment. The patient's level of functioning improved and body mass significantly decreased, with good tolerance of the pharmacotherapy. Lurasidone seems to be a promising treatment option in patients with treatment-resistant rapid cycling bipolar disorder.
鲁拉西酮是一种非典型抗精神病药物，被批准用于治疗精神分裂症和双相抑郁症。它似乎具有良好的代谢特征，引起不良相互作用的风险较低。在此，我们报告一例25岁女性患者，患有难治性超快速循环型双相情感障碍、肥胖症、甲状腺功能减退症和癫痫。由于主要为抑郁症状、偶尔出现短暂精神病性症状以及患者的躯体合并症，开始使用鲁拉西酮进行治疗。在鲁拉西酮治疗开始3周后观察到临床改善，8周后疾病的超快速循环病程停止。患者的功能水平有所改善，体重显著下降，药物治疗耐受性良好。鲁拉西酮似乎是难治性快速循环型双相情感障碍患者的一种有前景的治疗选择。
